A prospective, single-arm clinical study on the safety and efficacy of camrelizumab combined with apatinib and chemotherapy in the neoadjuvant therapy of potentially resectable stage II-III esophageal squamous cell carcinoma
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms GASTO-1093
- 15 Jan 2025 New trial record